Ennature Bio Pharma (ENNATURE) is loss-making over the last 12 months, losing ₹0.00 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹227.20, 14% below its 52-week high. It is a small-cap company with a market cap of ₹508 Cr, ranked 81st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 9.7% over the past year.
- ₹227.20
- ₹227.20
- ₹227.20
- ₹239.15
- 3.7K
Health check
- ReturnsBehind
−9.7% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- Growthn/a
Not enough yearly results to measure.
- Profitabilityn/a
Return ratios aren’t reported.
- Balance sheetn/a
Balance sheet figures aren’t reported.
- Red flags1 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹508 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- n/a
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- n/a
- Peers 14.7%
- ROCE
- n/a
- Peers 17.9%
- Debt to equity
- n/a
- EPS (TTM)
- n/a
- Face value ₹5
- OPM (TTM)
- 0.0%
- Net margin 0.0%
- Sales growth
- n/a
- Year-ago quarter not reported
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- n/a
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
About Ennature Bio Pharma
Ennature Bio Pharma Private Limited manufactures active pharmaceutical ingredients, branded nutraceutical ingredients, standardized botanical extracts, and nicotine derivatives. The company is based in Noida, India.
- Headquarters
- Noida
- Sector
- Healthcare
- ISIN
- INE2WCT01016
Price range
- Avg volume (3M)
- 54.2K
- 1-year return
- minus 9.7%
- From 52-week high
- minus 14.2%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| ENNATUREEnnature Bio Pharma | 227.20 | minus 5.00% | 508 | – | – | – | – | 0.0% | – | – | 0.00% | minus 9.7% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
| ₹ Cr | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| −0 | −0 | −0 | |
| −0 | −0 | −0 | |
| −0 | −0 | −0 |
Forecast
Balance sheet
| ₹ Cr | Mar 2025 | Mar 2026 |
|---|---|---|
| 0 | 0 | |
| −0 | −0 |
Cash flow
| ₹ Cr | Mar 2024 |
|---|---|
| −0 | |
| −0 | |
| −0 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company.
Major shareholders
Filings & events
News
No recent news coverage found.